found Documents: 618

Innovation Platform, Press Releases, RNS Announcements | 14 Jan 2021

Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Thursday, January 14, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presente

Download Press Release (PDF)

Innovation Platform, Press Releases, RNS Announcements | 11 Jan 2021

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

1 item

Hong Kong, Shanghai, San Diego & Florham Park, NJ: Monday, January 11, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”) today announce a strategic partnership to further dev

Download Press Release (PDF)

Corporate presentations, Event, Presentations | 9 Jan 2021

Corporate Presentation

2 items

Download Presentation (with Appendix) (PDF)Download Chinese Presentation (PDF)

Regulatory Notice, RNS Announcements | 31 Dec 2020

Blocklisting Six Monthly Return

1 item

London: Thursday, December 31, 2020: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech

View Announcement (PDF)

Regulatory Notice, RNS Announcements | 31 Dec 2020

Total Voting Rights

1 item

London: Thursday, December 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2020, the issued share capital of Chi-Med consisted of 727,722,215 ordinary shares of US$0.10 e

View Announcement (PDF)

Innovation Platform, Press Coverage, RNS Announcements | 30 Dec 2020

Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors

1 item

– Sulanda® is Chi-Med’s first oncology drug brought to market without a partnership and the company’s second oncology drug approved in China – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression o

View Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 29 Dec 2020

Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

1 item

– Company plans to complete rolling submission in the first half of 2021 – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acce

Download Press Release (PDF)

Group, Press Coverage, RNS Announcements | 22 Dec 2020

Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, December 22, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 39th Annual JP Morgan Heal

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 15 Dec 2020

Grant of Share Options under Share Option Scheme

1 item

London: Tuesday, December 15, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on December 14, 2020, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General

View Announcement (PDF)

Innovation Platform | 8 Dec 2020

Chi-Med Hosts Ground-breaking Ceremony for a Large-Scale Manufacturing Plant in Zhangjiang, Shanghai

1 item

Tuesday, December 8, 2020 Shanghai: Chi-Med (Nasdaq/AIM: HCM) today held a ground-breaking ceremony in Zhangjiang Hi-Tech Park, Shanghai, commencing construction of a large-scale manufacturing plant for innovative drugs. Representatives from the S

View Article (PDF)

Presentations, Scientific Publications | 5 Dec 2020

ASH2020: Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral PI3Kδ Inhibitor, in Chinese Patients with Relapsed/Refractory Lymphomas

2 items

Title: Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphoma Lead Author: Junning Cao, Zhiming Li, MD PhD, J

View Abstract (PDF)Download Presentation (PDF)

Regulatory Notice, RNS Announcements | 30 Nov 2020

Total Voting Rights

1 item

London: Monday, November 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2020, the issued share capital of Chi-Med consisted of 727,702,215 ordinary shares of US$0.10 eac

View Announcement (PDF)

Regulatory Notice, RNS Announcements | 27 Nov 2020

Notification of Dilution of Voting Rights

1 item

London: Friday, November 27, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding[1] in Chi-Med remains unchanged, at 332,478,770 ordinary shares

View Announcement (PDF)

Group, RNS Announcements | 17 Nov 2020

Chi-Med Announces US$100 Million Equity Investment by CPP Investments

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Hong Kong, Shanghai, & Florham Park, NJ: Tuesday

View Announcement (PDF)

Innovation Platform, Regulatory Notice, RNS Announcements | 5 Nov 2020

Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Thursday, November 5, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that initial analysis of the first in human HMPL-689 Phase I dose escalation study will be pre

Download Press Release (PDF)

Group, RNS Announcements | 30 Oct 2020

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Friday, October 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 30 Oct 2020

Total Voting Rights

1 item

London: Friday, October 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at October 30, 2020, the issued share capital of Chi-Med consisted of 711,025,545 ordinary shares of US$0.10 each,

View Announcement (PDF)

Regulatory Notice, RNS Announcements | 30 Sep 2020

Total Voting Rights

1 item

London: Wednesday, September 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 30, 2020, the issued share capital of Chi-Med consisted of 710,785,545 ordinary shares of US$0.1

View Announcement (PDF)

Presentations, Scientific Publications | 21 Sep 2020

The Lancet Oncology: Surufatinib SANET-p phase 3 study

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study Jianming Xu*, Lin Shen*, Chunmei Bai*, Wei Wang*, Jie Li, Xianjun Yu, Zhiping Li, Enxiao Li, Xianglin Yuan, Yihe

Presentations, Scientific Publications | 21 Sep 2020

The Lancet Oncology: Surufatinib SANET-ep phase 3 study

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study Jianming Xu*, Lin Shen*, Zhiwei Zhou, Jie Li, Chunmei Bai, Yihebali Chi, Zhiping Li, Nong Xu, Enxiao Li, T

Presentations, Scientific Publications | 20 Sep 2020

ESMO2020: Surufatinib for patients with advanced pancreatic NET (SANET-p)

1 item

Title: Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumors (SANET-p): a randomized, double-blind, placebo (P)-controlled Phase III trial (NCT02589821) Lead Author: Jianming Xu, Head of the Department of Gast

Download Presentation (PDF)

Innovation Platform, Press Releases, RNS Announcements | 20 Sep 2020

Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology

1 item

― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”) ― ― SANET-p results complement previously presented positive Pha

Download Press Release (PDF)

Presentations, Scientific Publications | 18 Sep 2020

ESMO2020: Phase1/1b Trial of Fruquintinib in Patients with Advanced Solid Tumors

1 item

Title: Phase (Ph) 1/1b Trial of Fruquintinib (Fru) in Patients (Pts) with Advanced Solid Tumors: Preliminary Results of the Dose Expansion (Exp) Cohort in Refractory Metastatic Colorectal Cancer (mCRC) Lead Author: N. Arvind Dasari, Asso

View Poster (PDF)

Presentations, Scientific Publications | 18 Sep 2020

ESMO2020: SANET-ep study subgroup analysis by Ki-67 and primary tumor origins

1 item

Title: Subgroup analysis by Ki-67 and primary tumor origins of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumors (SANET-ep) Lead Author: Zhiwei Zhou, Dir

View Poster (PDF)

Innovation Platform, Press Releases, RNS Announcements | 17 Sep 2020

Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 17, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of patients with

Download Press Release (PDF)

Innovation Platform, Press Releases, RNS Announcements | 4 Sep 2020

Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Friday, September 4, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated FRESCO-2, a Phase III registration study of fruquintinib for the treatment of patients with metas

Download Press Release (PDF)

Innovation Platform, Press Releases, RNS Announcements | 3 Sep 2020

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth fa

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 28 Aug 2020

Total Voting Rights

1 item

London: Friday, August 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 28, 2020, the issued share capital of Chi-Med consisted of 710,594,765 ordinary shares of US$0.10 each, w

View Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 24 Aug 2020

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 24, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studies of surufatinib and fruquintinib will be presented

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 12 Aug 2020

Grant of Share Options under Share Option Scheme

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, August 12, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on August 11, 2020, it granted share options under the Share Option Scheme conditionally adopte

View Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 10 Aug 2020

Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 10, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it received scientific advice from the European Medicines Agency's (“EMA”) Committee for

Download Press Release (PDF)

Group, RNS Announcements | 30 Jul 2020

Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs

1 item

– Strong global pipeline progress – three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib – – Two further NDAs submitted in China – savolitinib in

View Announcement (PDF)

Regulatory Notice, RNS Announcements | 30 Jul 2020

Block Admission Application

1 item

London: Thursday, July 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces an application has been made to the London Stock Exchange plc for a block admission of 30,221,458 ordinary shares, par value of US$0.1

Download Press Release (PDF)

Innovation Platform, Press Releases, RNS Announcements | 28 Jul 2020

Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China

1 item

Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an amendment to the 2013 License and Collaboration Agreeme

Download Press Release (PDF)

Innovation Platform, Press Releases, RNS Announcements | 28 Jul 2020

Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China

1 item

Hong Kong, Shanghai & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products Administration (“NMPA”) has granted Priority Review st

Download Press Release (PDF)

Innovation Platform, Press Releases, RNS Announcements | 24 Jul 2020

Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibitor in Patients with Hematological Malignancies in China

1 item

— HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med — Hong Kong, Shanghai & Florham Park, NJ: Friday, July 24, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has in

Download Press Release (PDF)

Regulatory Notice, RNS Announcements | 8 Jul 2020

TR-1: Standard form for notification of major holdings

1 item

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch

View Announcement (PDF)

Regulatory Notice, RNS Announcements | 7 Jul 2020

TR-1: Standard form for notification of major holdings

1 item

View Announcement (PDF)

Regulatory Notice, RNS Announcements | 7 Jul 2020

Notification of Dilution of Voting Rights

1 item

London: Tuesday, July 7, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding1 in Chi-Med remains unchanged, at 332,478,770 ordinary shares of par v

View Announcement (PDF)

Regulatory Notice, RNS Announcements | 29 Jun 2020

Blocklisting Six Monthly Return

1 item

London: Monday, June 29, 2020: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limite

View Announcement (PDF)

Group, RNS Announcements | 26 Jun 2020

Chi-Med to Announce 2020 Half-Year Financial Results

1 item

London: Friday, June 26, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its interim results for the six months ended June 30, 2020 on Thursday, July 30, 2020 at 12:00 noon British Summer Time (BST) (7:00 p

View Announcement (PDF)

Group, RNS Announcements | 25 Jun 2020

Chi-Med Announces US$100 Million Equity Investment by General Atlantic

1 item

View Announcement (PDF)

Innovation Platform, Press Releases, RNS Announcements | 18 Jun 2020

Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer

1 item

London: Thursday, June 18, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for the development of fruquintinib, for th

Download Press Release (PDF)

Commercial Platform, Press Releases, RNS Announcements | 9 Jun 2020

Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement

1 item

London: Tuesday, June 9, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), its 50:50 joint venture with Guangzhou Baiyu

Download Press Release (PDF)

Innovation Platform, Press Releases, RNS Announcements | 4 Jun 2020

Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review

1 item

London: Thursday, June 4, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the Independent Data Monitoring Committee (IDMC) of the FRUTIGA study of fruquintinib has completed a planned interim data review.

Download Press Release (PDF)

Corporate presentations, Event, Presentations | 1 Jun 2020

ASCO Investor Update

1 item

Press release released: May 29, 2020 (Fri) >> See press release here Presentation webcast & call: June 1, 2020 (Mon) 1pm GMT/ 8am EDT/ 8pm HKT >> Click here for the webcast replay

Download Presentation (PDF)

Innovation Platform, Press Releases, RNS Announcements | 1 Jun 2020

Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA

1 item

London: Monday June 1, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) for surufatinib f

Download Press Release (PDF)

Innovation Platform, Press Releases, RNS Announcements | 29 May 2020

Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

1 item

Press Release — First NDA filing of savolitinib globally — — Chi-Med seeking first-in-class Chinese marketing authorization for a selective MET inhibitor — London: Friday, May 29, 2020: Hutchison China MediTech Limi

Download Press Release (PDF)

Innovation Platform, Press Releases, RNS Announcements | 29 May 2020

Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20

1 item

Press Release ― Savolitinib in MET exon 14 skipping NSCLC efficacy evaluable patients demonstrated 49.2% ORR, 93.4% DCR and 9.6 months DoR, including 36% patients with more aggressive disease subtype ― ― Savolitinib vs. sunitinib stu

Download Press Release (PDF)

Innovation Platform, Press Releases, RNS Announcements | 26 May 2020

Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab

1 item

Press Release – Collaboration to explore multiple solid tumor cancer indications – – Initial development focused on multi-cohort trials in the U.S., Europe, China and Australia – LONDON, UK; CAMBRIDGE, Mass. and BEIJING

Download Press Release (PDF)

2 3 4 5 6 7 8 9 10 11 12 13